Development of immunotherapy in bladder cancer: present and future on targeting PD(L)1 and CTLA-4 pathways-Reference-Cited by-同舟云学术

Development of immunotherapy in bladder cancer: present and future on targeting PD(L)1 and CTLA-4 pathways

Published:2018-06-01 Issue:11 Volume:36 Page:1727-1740
ISSN:0724-4983
Container-title:World Journal of Urology
language:en
Short-container-title:World J Urol

Author:

Rouanne Mathieu,Roumiguié Mathieu,Houédé Nadine,Masson-Lecomte Alexandra,Colin Pierre,Pignot Géraldine,Larré Stéphane,Xylinas Evanguelos,Rouprêt Morgan,Neuzillet Yann

Funder

Association Française d'Urologie

Publisher

Springer Science and Business Media LLC

Subject

Urology

Link

http://link.springer.com/article/10.1007/s00345-018-2332-5/fulltext.html

Reference33 articles.

1. Sternberg CN, de Mulder PH, Schornagel JH, Théodore C, Fossa SD, van Oosterom AT et al (2001) Randomized phase III trial of high-dose-intensity methotrexate, vinblastine, doxorubicin, and cisplatin (MVAC) chemotherapy and recombinant human granulocyte colony-stimulating factor versus classic MVAC in advanced urothelial tract tumors: European Organization for Research and Treatment of Cancer Protocol no. 30924. J Clin Oncol 15(19):2638–2646

2. Witjes AJ, Lebret T, Compérat EM, Cowan NC, De Santis M, Bruins HM et al (2017) Updated 2016 EAU guidelines on muscle-invasive and metastatic bladder cancer. Eur Urol 71:462–475

3. Rouprêt M, Neuzillet Y, Masson-Lecomte A, Colin P, Compérat E, Dubosq F et al (2016) CCAFU French national guidelines 2016–2018 on bladder cancer. Prog Urol 27(Suppl 1):S67–S91

4. Bellmunt J, Orsola A, Leow JJ, Wiegel T, De Santis M, Horwich A (2014) Bladder cancer: ESMO practice guidelines for diagnosis, treatment and follow-up. Ann Oncol 25(3):40–48

5. Dash A, Galsky MD, Vickers AJ, Serio AM, Koppie TM, Dalbagni G, Bochner BH (2006) Impact of renal impairment on eligibility for adjuvant cisplatin-based chemotherapy in patients with urothelial carcinoma of the bladder. Cancer 107:506–513

Cited by 73 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. A New Strategy to Authenticate Prognosis and Tumor Immunity Model Based on Cancer-Associated Fibroblasts lncRNA in Bladder Cancer;Journal of Biomedical Nanotechnology;2024-07-01

2. The clinical significance of PD-1 expression in patients with bladder cancer without lymph node metastasis: a comparative study with drained lymph nodes and tumor tissues;International Journal of Neuroscience;2024-05-14

3. Why Y matters? The implication of loss of Y chromosome in blood and cancer;Cancer Science;2024-01-23

4. Dendritic nanoparticles for immune modulation: a potential next-generation nanocarrier for cancer immunotherapy;Nanoscale;2024

5. A Prognostic Biomarker for Bladder Cancer Correlated with Immune Infiltration Is PAEP;Journal of Biosciences and Medicines;2024